The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein.
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)
 
Philippe L. Bedard
Consulting or Advisory Role - Genentech/Roche (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Oncothyreon (Inst); PTC Therapeutics (Inst); Sanofi (Inst); SERVIER (Inst); SignalChem (Inst)
 
Geoffrey Shapiro
Consulting or Advisory Role - G1 Therapeutics; Lilly; Pfizer; Vertex
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly; Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst)
 
Todd Michael Bauer
Employment - Sarah Cannon Research Institute; Tennessee Oncology
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunogen (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Principa Biopharma (Inst); Stemline Therapeutics (Inst)
 
Amy Prawira
No Relationships to Disclose
 
Oscar Laskin
Employment - R2D Pharma SVS LLC
Stock and Other Ownership Interests - PTC Therapeutics
Consulting or Advisory Role - PTC Therapeutics
 
Marla Weetall
Employment - PTC Therapeutics
Stock and Other Ownership Interests - PTC Therapeutics
Patents, Royalties, Other Intellectual Property - PTC Therapeutics (Inst)
 
John Baird
Employment - PTC Therapeutics
Stock and Other Ownership Interests - PTC Therapeutics
Patents, Royalties, Other Intellectual Property - PTC Therapeutics (Inst)
 
Art Branstrom
Employment - PTC Therapeutics
Patents, Royalties, Other Intellectual Property - PTC Therapeutics (Inst)
 
Edward O'Mara
Employment - PTC Therapeutics
Stock and Other Ownership Interests - PTC Therapeutics
Patents, Royalties, Other Intellectual Property - PTC Therapeutics
 
Robert J. Spiegel
Employment - PTC Therapeutics
Leadership - Geron; PTC Therapeutics; Sucampo Pharmaceuticals
Stock and Other Ownership Interests - Edge Therapeutics, Inc.; Geron; PTC Therapeutics; Sucampo Pharmaceuticals
Consulting or Advisory Role - PTC Therapeutics